Pericarditis Market Projected to Grow Radiantly by 2030

Pune, India, February 8, 2022/MRFR Press Release/- Market Research Future published a Half-Cooked research report on “Pericarditis Market Research Report - Forecast to 2030 ” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2030 .

Johnson & Johnson Services, Inc., Boehringer Ingelheim International GmbH, Amgen, Inc., Sanofi Aventis, Abbott Laboratories, AstraZeneca, Bayer HealthCare Pharmaceuticals LLC, Pfizer, Inc., Reckitt Benckiser Group plc, Novartis International AG, Daiichi Sankyo Company, Limited, AbbVie Inc., GlaxoSmithKline plc, Merck & Co., Inc., Hoffmann-La Roche AG, Eli Lily and Company, Boston Scientific Corporation, KONINKLIJKE PHILIPS N.V, B. Braun Melsungen AG, Becton, Dickinson and Company (BD), and others are some of the prominent players at the forefront of competition in the pericarditis market and are profiled in MRFR Analysis.

Pericarditis Market - Overview

The pericarditis market is growing mainly due to growing awareness, and rising adoption of anti-inflammatory drugs. According to a recent study report published by the Market Research Future, the pericarditis market is booming and expected to gain prominence over the forecast period. The market is forecast to demonstrate a spectacular growth by 2030, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period.

Pericarditis is an inflammation of the pericardium sac. The major causes of pericarditis includes heart surgery, heart attack, trauma, tumours, infections, radiation, and various autoimmune diseases. The pericarditis is classified by type as chronic, acute, and recurrent pericarditis. Acute pericarditis occurs suddenly and does not last long whereas chronic pericarditis begins when the symptoms develop more gradually and persist for long duration of weeks. Acute pericarditis is diagnosed in nearly 0.1% of patients admitted in hospitals for chest pain, and it presents most commonly in men 20 to 50 years of age. The major diagnostic procedures used for pericarditis are electrocardiogram (ECG), chest X-ray, echocardiogram, computerized tomography (CT), and cardiac magnetic resonance imaging (MRI). The treatment approach for pericarditis depends on the severity of the condition. For the reduction of inflammation and swelling associated with pericarditis, pain relievers, and corticosteroids are usually prescribed. Colchicine is also prescribed as a treatment for recurrent symptoms or acute pericarditis. In more severe cases, such as cardiac tamponade, pericardiocentesis, and pericardiectomy are recommended to relieve fluid buildup.

Due to presence of major market players in this region such as AstraZeneca, and Novartis AG, and high healthcare expenditure the Americas dominate the global pericarditis market. According to the Centres for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Notably, increasing prevalence of pericarditis, and related complications, rising research and development expenditure are the primary drivers for pericarditis market. According to the European Federation of Pharmaceutical Industries and Association, in the year of 2016, the R&D expenditure in the European Pharmaceutical Industry was EUR 35000 million. The Indian Brand Equity Foundation (IBEF) has also suggested that in 2016 the generics market of India stood at USD 26.1 billion.

Other push factors such as, rising cases of heart attack, and various autoimmune diseases, increasing urbanization and changing lifestyles, advantages associated with botanical drugs over other drugs, improvement in reimbursement policies, ensuring adherence to recommended dietary requirements, treatment of illnesses, developing retail and pharmaceutical industries, preventing occurrence of disease, and rapid advancements in product offerings are also fuelling the growth of the market.

Despite these drivers, presence of misbranded drugs, expiration of blockbuster drugs, side effects associated with anti-inflammatory drugs, surgical interventions, strict FDA regulations, are expected to hinder the growth of the market during the forecast period.

Explore In-depth Details: Pericarditis Market Research Report

Pericarditis Market - Competitive Analysis

The pericarditis market is currently dominated by various players. Due to rising cases of heart attacks, and related complications various existing and new marketers are continuously coming up with advanced products to control various health conditions. The global pericarditis market is currently dominated by numerous players.

Novartis AG is one of them by holding a strong share in the market. The company’s stronghold is largely attributed to its innovative and sustainable products. Novartis is one of the largest pharmaceutical companies. Novartis operates through three operating divisions, namely; Pharmaceuticals, Alcon (eye care) and Sandoz (generics). The major strategies adopted by the company is to focus on science-based innovation to deliver better patient outcomes, and investment in research and development focused on areas of unmet medical need. On August 27, 2017, Novartis phase III CANTOS study demonstrated that by targeting inflammation with ACZ885, cardiovascular risk can be reduced.

AstraZeneca is another renowned market player in Pericarditis market. AstraZeneca offers wide range of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. On February 25, 2015, AstraZeneca and Orca Pharmaceuticals announced a three year collaboration for the development of inhibitors of retinoic acid–related orphan nuclear receptor gamma.